Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-021-25480-z
Keywords
-
Categories
Funding
- Rosalind Franklin Institute
- Rosalind Franklin Institute EPSRC [EP/S025243/1]
- Wellcome Trust [100209/Z/12/Z]
- EPA Cephalosporin Fund
- Oxford COVID-19 Research Response Fund
- MRC [MR/W005611/1]
- G2P-UK
- US Food and Drug Administration (USA) [75F40120C00085]
- Wellcome Trust [100209/Z/12/Z] Funding Source: Wellcome Trust
- MRC [MR/W005611/1] Funding Source: UKRI
Ask authors/readers for more resources
Nanobodies engineered as homotrimers show promising potential in neutralizing SARS-CoV-2 viral strains for COVID-19 treatment, especially when administered through respiratory routes. The study characterizes four nanobodies with high affinity for the receptor binding domain of the spike protein, demonstrating efficacy in inhibiting disease progression in animal models.
SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration. We report four nanobodies (C5, H3, C1, F2) engineered as homotrimers with pmolar affinity for the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Crystal structures show C5 and H3 overlap the ACE2 epitope, whilst C1 and F2 bind to a different epitope. Cryo Electron Microscopy shows C5 binding results in an all down arrangement of the Spike protein. C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa). Administration of C5-trimer via the respiratory route showed potent therapeutic efficacy in the Syrian hamster model of COVID-19 and separately, effective prophylaxis. The molecule was similarly potent by intraperitoneal injection. Neutralizing nanobodies (Nb) are of considerable interest as therapeutic agents for COVID-19 treatment. Here, the authors functionally and structurally characterize Nbs that bind with high affinity to the receptor binding domain of the SARS-CoV-2 spike protein and show that an engineered homotrimeric Nb prevents disease progression in a Syrian hamster model of COVID-19 when administered intranasally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available